

Draft for consultation

## Type 2 diabetes in adults: management (medicines update)

**NICE Guideline: Acknowledgements**

*NICE guideline GID-NG10336*

*Authors and contributors*

*August 2025*

*Draft for consultation*

*Commissioned by the National Institute for  
Health and Care Excellence*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2025. All rights reserved. Subject to [Notice of Rights](#).

ISBN:

Contents

**Guideline developers ..... 5**

    Members of the NICE guideline committee:..... 5

    Members of NICE team: ..... 6

    Additional acknowledgements ..... 7

# Guideline developers

## Members of the NICE guideline committee:

Name	Role
Waqar Shah	Committee Chair (from Guideline Committee meeting 3)
Simon Mackenzie	Committee Chair (until Guideline Committee meeting 2)
Dan Cuthbertson	Topic Adviser
Chirag Bakhai	GP
Neel Basudev	GP
Catherine Bewsey	Practitioner Psychologist
Mimi Chen	Consultant Diabetologist
Sithembile Thokozile Chinaire	Diabetes Nurse
Hussain Contractor	Cardiologist
Anne Dornhorst	Consultant Diabetologist
Hugh Gallagher	Renal Physician
Natasha Jacques	Pharmacist
Sallianne Kavanagh	Pharmacist and Vice Chair
Sharon McCarthy	Diabetes Nurse
Dominic Taylor	Renal Physician
John Turner	Lay member
Soon Song	Consultant Diabetologist
Annette Swinkels	Lay member
Gosia Wamil	Cardiologist (Co-opted)

**Members of NICE team:**

<b>Name</b>	<b>Role</b>
Astrid Aregui	Senior Guidance Content Designer
Serena Carville	Guideline Lead
Annette Chalker	Technical Analyst
Angela Cooper	Technical Analyst
Amy Crisp	Senior Project Manager
Joseph Crutwell	Technical Analyst
Sarah Dwyer	Technical Analyst
Linyun Fou	Technical Analyst
Rupert Franklin	Guideline Commissioning Manager
Victoria Freeman	Systematic Reviewer
Sarah Glover	Senior Information Specialist
James Hall	Senior Guidance Content Designer
James Hawkins	Health Economics Adviser
Sarah Matthews	Technical Analyst
Lina Manounah	Technical Analyst
Lisa Miles	Technical Analyst
Gregory Moran	Medicines Adviser
Patrick Muller	Technical Adviser (Data Science), who contributed Real World Evidence to the guideline update
Caroline Mulvihill	Topic Lead
Tayyaba Mumtaz	Trainee Technical Analyst
Adam O'Keefe	Project Manager
Lesley Owen	Health Economics Adviser, who contributed Real World Evidence to the guideline update
Sade Naku	Health Economist
Nancy Pursey	Trainee Technical Analyst
Muksitur Rahman	Health Economist
Joseph Runicles	Information Specialist
Toby Sands	Technical Analyst
Eleanor Samarasekera	Senior Technical Analyst
Meena Tafazzoli	Technical Analyst
Emily Terrazas-Cruz	Senior Technical Analyst
Melina Vasileiou	Senior Systematic Reviewer
Magdalena Watras	Medicines Adviser
Philip Williams	Business Analyst, Resource Impact Assessment
George Wood	Senior Technical Analyst
David Wonderling	Senior Health Economics Adviser
Jonathan Wray	Senior Analyst, Healthcare Data and Analytics, who contributed Real World Evidence to the guideline update
Michellie Young	Technical Analyst
Madelaine Zucker	Technical Analyst

## Additional acknowledgements

The development of this guideline was greatly assisted by the following people:

- The NICE Guidelines Technical Support Unit, at University of Bristol, particularly Hugo Pedder, Beatrice Downing and Nicky Welton, who provided advice, models, inconsistency checking and quality assurance for the network meta-analyses included in this update.
- Dr Eleanor Yelland and Dr Robert Willans who contributed to the CPRD protocol, acquiring data and assisting in its analysis and interpretation which informed the health economic analysis and the health inequalities work.
- The Diabetes Informatics and Epidemiology Group at the University of Edinburgh in particular Professor Helen Colhoun, Dr Stuart McGurnaghan, Dr Andrew Wilson, Dr Tom Caparrotta and Mr Andrew Wilson who provided data and performed analyses for informing the economic analysis for this update.
- Britta Tendal Jeppesen, Suetonia Palmer, Heath White, Sheyu Li and others who were involved in the Type 2 Diabetes Medicines Partnership, a collaboration between the Alliance for Living Evidence, Australian Living Evidence Collaboration (Monash University), MAGIC Evidence Ecosystem Foundation, Duodecim and the Future Evidence Foundation. They provided advice and data, which was checked against while conducting data extraction
- Dr Michael Ni'Man, who provided expert testimony on the evidence for the trans community in relation to type 2 diabetes.